KevinMD.com: Social media’s leading physician voice
The KevinMD newsletterReal physician voices, twice a weekFree, and one click to unsubscribe.
Subscribe free →

Fear Mongering At The FDA

Fear Mongering At The FDA

I haven’t seen the preliminary Naproxyn data that the FDA based its press release on, but this article suggests that the increase in cardiac events wasn’t even statistically significant:

In the Alzheimer’s study, though, there was no increase in heart risk for long-term Celebrex users. There was a slight increase in heart risk for naproxen users, but the increase was so small that it may have been a chance occurrence. It was not the kind of data on which decisions involving many thousands of patients should have been made.

Share this articleLinkedInFacebookXEmail

Real physician voices, twice a week

Free, and one click to unsubscribe.

No spam. We never share your email.